A new trial design to accelerate tuberculosis drug development : the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)

Simple item page
dc.contributor.authorPhillips, Patrick P. J.en_ZA
dc.contributor.authorDooley, Kelly E.en_ZA
dc.contributor.authorGillespie, Stephen H.en_ZA
dc.contributor.authorHeinrich, Norberten_ZA
dc.contributor.authorStout, Jason E.en_ZA
dc.contributor.authorNahid, Payamen_ZA
dc.contributor.authorDiacon, Andreas H.en_ZA
dc.contributor.authorAarnoutse, Rob E.en_ZA
dc.contributor.authorKibiki, Gibson S.en_ZA
dc.contributor.authorBoeree, Martin J.en_ZA
dc.contributor.authorHoelscher, Michaelen_ZA
dc.date.accessioned2017-01-24T10:35:16Z
dc.date.available2017-01-24T10:35:16Z
dc.date.issued2016-03-23
dc.date.updated2016-12-09T12:08:11Z
dc.descriptionCITATION: Phillips, P. P. J., et al. 2016. A new trial design to accelerate tuberculosis drug development : the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). BMC Medicine. 14:51, doi:10.1186/s12916-016-0597-3.
dc.descriptionThe original publication is available at https://bmcmedicine.biomedcentral.com
dc.description.abstractBackground: The standard 6-month four-drug regimen for the treatment of drug-sensitive tuberculosis has remained unchanged for decades and is inadequate to control the epidemic. Shorter, simpler regimens are urgently needed to defeat what is now the world’s greatest infectious disease killer. Methods: We describe the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP) as a novel hybrid phase II/III trial design to accelerate regimen development. In the Phase IIC STEP trial, the experimental regimen is given for the duration for which it will be studied in phase III (presently 3 or 4 months) and patients are followed for clinical outcomes of treatment failure and relapse for a total of 12 months from randomisation. Operating characteristics of the trial design are explored assuming a classical frequentist framework as well as a Bayesian framework with flat and sceptical priors. A simulation study is conducted using data from the RIFAQUIN phase III trial to illustrate how such a design could be used in practice. Results: With 80 patients per arm, and two (2.5 %) unfavourable outcomes in the STEP trial, there is a probability of 0.99 that the proportion of unfavourable outcomes in a potential phase III trial would be less than 12 % and a probability of 0.91 that the proportion of unfavourable outcomes would be less than 8 %. With six (7.5 %) unfavourable outcomes, there is a probability of 0.82 that the proportion of unfavourable outcomes in a potential phase III trial would be less than 12 % and a probability of 0.41 that it would be less than 8 %. Simulations using data from the RIFAQUIN trial show that a STEP trial with 80 patients per arm would have correctly shown that the Inferior Regimen should not proceed to phase III and would have had a high chance (0.88) of either showing that the Successful Regimen could proceed to phase III or that it might require further optimisation. Conclusions: Collection of definitive clinical outcome data in a relatively small number of participants over only 12 months provides valuable information about the likelihood of success in a future phase III trial. We strongly believe that the STEP trial design described herein is an important tool that would allow for more informed decision-making and accelerate regimen development.
dc.description.urihttps://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0597-3
dc.description.versionPublisher's version
dc.format.extent11 pages
dc.identifier.citationPhillips, P. P. J., et al. 2016. A new trial design to accelerate tuberculosis drug development : the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). BMC Medicine. 14:51, doi:10.1186/s12916-016-0597-3
dc.identifier.issn1741-7015 (Online)
dc.identifier.otherdoi:10.1186/s12916-016-0597-3
dc.identifier.urihttp://hdl.handle.net/10019.1/100508
dc.language.isoen_ZAen_ZA
dc.publisherBioMed Central
dc.rights.holderAuthors retain copyright
dc.subjectTuberculosis -- Treatmenten_ZA
dc.subjectDrugs -- Testingen_ZA
dc.subjectDrug resistance in microorganismsen_ZA
dc.titleA new trial design to accelerate tuberculosis drug development : the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)en_ZA
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
phillips_new_2016.pdf
Size:
2.6 MB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.95 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Medical Physiology)